Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TNG908 |
Synonyms | |
Therapy Description |
TNG908 is an MTAP-null selective PRMT5 inhibitor, which potentially reduces growth of tumors with MTAP deletion (Cancer Res 2022;82(12_Suppl):Abstract nr 3941). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TNG908 | TNG-908|TNG 908 | PRMT5 Inhibitor 17 | TNG908 is an MTAP-null selective PRMT5 inhibitor, which potentially reduces growth of tumors with MTAP deletion (Cancer Res 2022;82(12_Suppl):Abstract nr 3941). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05275478 | Phase Ib/II | TNG908 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | Active, not recruiting | USA | FRA | 0 |